Currently, Nektar Therapeutics [NKTR] is trading at $1.38, up 6.98%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NKTR shares have gain 6.15% over the last week, with a monthly amount glided 6.15%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Rodman & Renshaw started tracking the stock with Buy rating on June 28, 2024, and set its price target to $2. TD Cowen upgraded its rating to a Outperform. Jefferies upgraded its rating to a Hold and reduced its price target to $1 on May 10, 2023. Jefferies downgraded its rating to Underperform for this stock on February 24, 2023, and downed its price target to $1.50. In a note dated August 08, 2022, JP Morgan downgraded an Underweight rating on this stock.
This stock has fluctuated between a low of $0.41 and a high of $1.93 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $1.38 at the most recent close of the market. An investor can expect a potential return of 1113.77% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Trailing Twelve Months sales for Nektar Therapeutics [NASDAQ:NKTR] were 93.16M which represents 14.59% growth. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -1.57%, Pretax Profit Margin comes in at -1.9%, and Net Profit Margin reading is -1.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -1.43 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.62.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3200 points at the first support level, and at 1.2600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4100, and for the 2nd resistance point, it is at 1.4400.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nektar Therapeutics [NASDAQ:NKTR] is 5.15. In addition, the Quick Ratio stands at 4.90 and the Cash Ratio stands at 0.24. Considering the valuation of this stock, the price to sales ratio is 2.73, the price to book ratio is 3.19.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on Aug 19 ’24 when 6866.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Aug 19 ’24 to sell 5651.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 14881.0 shares on Aug 19 ’24.
